Generic Name and Formulations:
Bacitracin 50,000units/vial; pwd for IM inj after reconstitution.
X-GEN Pharmaceuticals, Inc
Indications for BACIIM:
Susceptible infections due to staphylococci, including pneumonia and empyema in infants.
Give by IM inj into upper outer quadrant of buttocks. Infants: <2.5kg: 900units/kg per day in 2–3 divided doses; >2.5kg: 1,000units/kg per day in 2–3 divided doses.
Renal impairment. Monitor renal function before and daily during therapy; discontinue if renal toxicity occurs. Ensure adequate hydration.
Avoid other nephrotoxic drugs (eg, aminoglycosides, polymyxin B, colistin).
Nephrotoxicity (eg, albuminuria, azotemia, cylinduria), nausea, vomiting, rash, inj site pain.
Clinical Pain Advisor Articles
- Risks Associated With Co-Administration of Aspirin and Other NSAIDs
- Stages of Low Back Pain Have Specific Sets of Clinical Indicators
- FDA Approves Aimovig for Migraine Prevention
- First Non-Opioid Drug Approved for Managing Opioid Withdrawal Symptoms
- Pain Interference Associated With Depression, Pain Self-Efficacy in Chronic Musculoskeletal Pain
- Effect of Prescription Drug Monitoring Programs on Fatal, Nonfatal Drug Overdoses
- Standardized SCS Workflow May Effectively Alleviate Failed Back Surgery Syndrome-Related Pain
- Marijuana Legalization and Opioid Prescribing Rates
- Medical Marijuana Users More Likely to Use Prescription Drugs for Medical, Nonmedical Purposes
- Interbrain Coupling During Handholding Associated With Analgesia, Empathy
- Remission Rates and Predictors of Chronic Headache
- Overuse and Underuse of Imaging Common in Low Back Pain Management
- Unit-Dose Packaging of Buprenorphine-Naloxone Effective on Unintentional Pediatric Exposure
- Language Used in Medical Record Can Affect Patient Care
- Opioid-Related Adverse Drug Events Associated With Worse Patient, Cost Outcomes